z-logo
Premium
SU‐E‐T‐691: Shielding Evaluation of a Treatment Room with An Electronic Brachytherapy System
Author(s) -
IbanezRosello B,
Bautista J,
CandelaJuan C,
Villaescusa J,
Ballester F,
PerezCalatayud J
Publication year - 2015
Publication title -
medical physics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.473
H-Index - 180
eISSN - 2473-4209
pISSN - 0094-2405
DOI - 10.1118/1.4925054
Subject(s) - brachytherapy , dosimetry , electromagnetic shielding , radiation , nuclear medicine , dose rate , materials science , leakage (economics) , radiation protection , ionization chamber , beam (structure) , optics , medical physics , ionization , physics , radiation therapy , medicine , radiology , economics , composite material , ion , quantum mechanics , macroeconomics
Purpose: Esteya™ (Elekta) is a brachytherapy electronic system used for treating skin cancer lesions. This unit is based on a 69.5 kV X‐ray source and a surface applicator which produces a circular beam of a specific diameter, which varies from 1 to 3 cm. This study aims to establish the radiation protection measures for the system. Methods: A characterization of the scattered and leakage radiation of the system was implemented by means of experimental measurements. The scattered radiation measurements were performed with a Berthold LB133 ionization chamber, evaluating the dose rate for different distances from the applicator surface. The patient was simulated through water equivalent solid material of 9 cm thickness. Leakage was evaluated by setting 2 cm thick lead at the output of the radiation beam.From the obtained measurements, the necessary shielding has been estimated following the Report 147 by ICRP, and particularizing those values to a hypothetical installation. The dose received by a person who exceptionally would have to eventually stay inside the room with the patient was also analyzed. Results: The scattered dose rate ranges from 17.3 mSv/h at 0.25 m distance to 0.1 mSv/h at 2.5 m. Leakage represents 0.24% of the scattered dose rate. With these measurements and some assumptions on the workload and dimensions of a hypothetical treatment room it was estimated that the overall lead shielding for primary and secondary barriers was well below 1 mm, although it depends on each particular case. The overall absorbed dose to an eventual companion placed 0.5 m away from the patient is below 2 mSv after the complete treatment. Conclusion: Esteya shielding requirements are minimal, which facilitate its integration into conventional rooms. Furthermore, the presence of a companion during treatment is possible if absolutely necessary, recommending the use of a leaded apron and thyroid shielding.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom